MetLife Investment Management
IONS icon

MetLife Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

MetLife Investment Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$696K Sell
8,776
-448
-5% -$33.7K ﹤0.01% 1730
2026
Q1 		$693K Sell
9,224
-450
-5% -$35.5K ﹤0.01% 1595
2025
Q4 		$765K Buy
9,674
+246
+3% +$18.5K ﹤0.01% 1580
2025
Q3 		$617K Buy
9,428
+267
+3% +$13K ﹤0.01% 1702
2025
Q2 		$362K Buy
9,161
+17
+0.2% +$556 ﹤0.01% 1843
2025
Q1 		$276K Sell
9,144
-16
-0.2% -$524 ﹤0.01% 2021
2024
Q4 		$320K Sell
9,160
-203
-2% -$7.59K ﹤0.01% 2039
2024
Q3 		$375K Buy
9,363
+514
+6% +$23.9K ﹤0.01% 1942
2024
Q2 		$422K Buy
8,849
+1,008
+13% +$41.3K ﹤0.01% 1818
2024
Q1 		$340K Buy
7,841
+24
+0.3% +$1.14K ﹤0.01% 1903
2023
Q4 		$395K Sell
7,817
-109
-1% -$5.22K ﹤0.01% 1826
2023
Q3 		$360K Buy
7,926
+4
+0.1% +$165 ﹤0.01% 1832
2023
Q2 		$325K Sell
7,922
-178
-2% -$6.84K ﹤0.01% 1965
2023
Q1 		$289K Buy
8,100
+18
+0.2% +$676 ﹤0.01% 1990
2022
Q4 		$305K Sell
8,082
-205
-2% -$8.62K ﹤0.01% 1976
2022
Q3 		$367K Hold
8,287
– – ﹤0.01% 1864
2022
Q2 		$307K Sell
8,287
-292
-3% -$11K ﹤0.01% 2007
2022
Q1 		$318K Buy
+8,579
New +$281K ﹤0.01% 2065
2019
Q2 		– Sell
-513
Closed -$41.8K – 2518
2019
Q1 		$41.8K Buy
513
+343
+202% +$22.1K ﹤0.01% 2364
2018
Q4 		$9.19K Sell
170
-2
-1% -$102 ﹤0.01% 2386
2018
Q3 		$8.87K Buy
+172
New +$8.08K ﹤0.01% 2455

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

MetLife Investment Management's IONS Position: Q2 2026 in Review

MetLife Investment Management reduced its Ionis Pharmaceuticals (IONS) stake by 4.9% in Q2 2026, selling an estimated $33.7K and leaving 8,776 shares worth $696K. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

MetLife Investment Management first reported a position in IONS in Q3 2018 and has held it in 21 quarters since. The position peaked at $765K in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • MetLife Investment Management held 8,776 shares of Ionis Pharmaceuticals worth $696K as of Q2 2026.
  • MetLife Investment Management sold 448 Ionis Pharmaceuticals shares in Q2 2026, an estimated $33.7K.
  • Ionis Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1730 holding.
  • MetLife Investment Management first reported a position in Ionis Pharmaceuticals in Q3 2018 and has held it in 21 quarters since.
  • MetLife Investment Management's Ionis Pharmaceuticals position peaked at $765K in Q4 2025.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.